Galectin Therapeutics Inc. (GALT)

[biotech2010]

Why are all of you amateurs playing trial design experts?

GALT has a very strong scientific advisory team, including Dr Friedman, and they know far more about this than any of us.

I am as disappointed in the FX trial data as anyone else (and sold more than half of my shares to buy CNAT shares when the data was released, thanks staccani) but you can't assume the FX failure (which is based as much upon the way the results were measured as anything else) will have any impact on the CX trial data.

They aren't going to make any changes in the protocol for CX, it would mean starting over, from scratch, since more than half of the patients have already completed more than 6 months of therapy (we don't know how many have completed the entire therapy but the count increases on a regular basis).

They still have the specific, positive results for Alpha2 Macroglobulin from the Phase 1 trial and the right endpoint for the CX trial-at this point in time all one can do is either hedge your bets (as I did) or sell your shares and move on, nothing you say to the company is going to change the chosen path.